Chat with us, powered by LiveChat


Bronchodilators Market Report


Bronchodilators Market by Drug Class (Beta-Adrenergic Bronchodilators, Xanthine Derivatives, and Anticholinergic Bronchodilators), Route of Administration (Oral, Nasal, and Injectable), Disease (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), and Region (North America, Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2023-2032


Pages: 290

Oct 2023

Bronchodilators Overview

Breathing disorders including asthma and chronic obstructive pulmonary disease are managed using a class of drugs called bronchodilators. These medical conditions cause clients airways narrowing which makes breathing challenging. In order to open up the airways and increase airflow, bronchodilators function by relaxing the muscles around the airways. As a result, symptoms including snorting and breathlessness and coughing are reduced. Both beta-agonists and anticholinergics are common forms of bronchodilators, beta-agonists allow the muscles of the airways to relax and widen as a result of activating receptors in the airways. They offer quick relief and are frequently used as emergency substances. On the other side anticholinergics prevent the activity of the receptor acetylcholine, which results in the relaxation of the airway muscles and enlargement of the airways. 

Global Bronchodilators Market Analysis

The global bronchodilators market size was $22.52 billion in 2022 and is predicted to grow with a CAGR of 3.5%, by generating a revenue of $31.47 billion by 2032.

COVID-19 Impact on Global Bronchodilators Market

The emergence of Covid-19 significantly affected the bronchodilators market. These medications, commonly used by individuals with respiratory conditions like asthma and COPD, saw shifts in demand and trends due to the pandemic. There was increased awareness of the need of preserving respiratory health because the virus predominantly affects the respiratory system. As a result, bronchodilators saw a rise in demand due to people’s rising concerns about lung function. People with pre-existing respiratory conditions were particularly cautious driving a surge in demand for these medications.

However, disruptions in the healthcare system and supply chains had ripple effects. Lockdowns, restrictions, and overwhelmed medical facilities led to challenges in accessing healthcare services and medications. This impacted the distribution and availability of bronchodilators, causing fluctuations in the market. Telemedicine and online pharmacies emerged as alternatives for obtaining medications. This shift in patient behavior also influenced how bronchodilators were prescribed and purchased. 

Growing Prevalence of Respiratory Diseases to Drive the Market Growth

Increased prevalence of respiratory diseases, such as COPD and asthma among people across the globe is a major factor driving the growth of the bronchodilators market growth. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death across the globe, causing 3.23 million deaths in 2019. Therefore, the rising burden of COPD leads to boosting demand for bronchodilators. Besides, bronchodilators offer notable benefits for individuals with respiratory conditions and are thus high in demand due to the growing awareness of people about lung disease treatment. Bronchodilators when used as directed help widen airways in the lungs making it easier for air to flow in and out thereby improving breathing. These medications work rapidly providing quick relief from symptoms like shortness of breath & wheezing and chest tightness allowing individuals to resume normal activities. Moreover, other factors, such as the increasing geriatric population, rise in disposable income, and increased usage of bronchodilators for the treatment of cystic fibrosis are predicted to boost the market growth during the forecast period.

Lack of Awareness and High Costs to Restrain the Market Growth

Lack of patient awareness about the disease and differentiated symptoms could curb the growth of the global bronchodilators market over a forecast period. Besides, the huge expenditure required for treating chronic bronchitis is likely to hamper the market growth. Moreover, bronchodilators do not address the root causes of respiratory problems, and their efficacy can vary from person to person. Bronchodilators can provide temporary relief by opening airways, but they don't address the root causes of respiratory problems potentially delaying proper treatment, which can be a limiting growth factor.

Advanced Clinical Research and Innovative Strategies to Drive Excellent Opportunities

Several market players are engaged in the implementation of strategic initiatives, thus contributing to market growth. Key market players are investing widely to develop varied inhalers and nebulizers that will provide easy access to patients. The availability of ultrasonic nebulizers and others, which consist of advanced technology creates opportunity for the market. Additionally, with an aging population there is an opportunity to design bronchodilators that consider the physiological changes associated with aging offering improved therapeutic benefits for elderly patients. Developing cost-effective bronchodilator options and ensuring their availability in underserved regions can make essential respiratory care accessible to a broader population. Creating environmentally friendly inhalers and bronchodilator formulations with reduced carbon footprint and eco-friendly materials aligns with growing sustainability trends. All these factors are projected to develop growth opportunities for the bronchodilators market.

Global Bronchodilators Market Share, by Drug Class, 2022

The beta-adrenergic bronchodilators sub-segment accounted for the highest market share in 2022. This is mainly because the beta-adrenergic bronchodilators provide immediate comfort to people having breathing problems by removing the tightness that is a symptom of illnesses like asthma and chronic obstructive pulmonary disease. One significant advantage is the rapid onset of action. Beta-adrenergic bronchodilators, such as albuterol, exert their effects within minutes, providing immediate relief during acute episodes. Additionally, their versatility in administration, available as inhalers or nebulizers, enables patients to use them conveniently as needed. The widespread acceptance of beta-adrenergic bronchodilators stems from their favourable risk-benefit profile. They generally exhibit a well-tolerated side effect profile with adverse effects, such as tremors and tachycardia being manageable and temporary.

Global Bronchodilators Market Share, by Route of Administration, 2022

The nasal sub-segment accounted for the highest market share in 2022. The dominance of the nasal route of administration in bronchodilators can be attributed to its unique advantages. This route offers rapid and direct access to the bloodstream, bypassing the digestive system and avoiding potential degradation of the drug. Nasal administration allows for quick onset of action, crucial in bronchodilator use for immediate relief of respiratory distress. Furthermore, nasal administration is non-invasive and avoids the discomfort of injections, making it more patient-friendly, especially for individuals who have difficulties with inhalation devices. The nasal mucosa provides a large surface area with a rich blood supply, enhancing drug absorption and distribution. This method is particularly beneficial for paediatric and geriatric populations. The dominance of nasal administration in bronchodilators reflects the balance between the rapid onset of action, patient convenience, and effective drug delivery.

Global Bronchodilators Market Share, by Disease, 2022

The asthma sub-segment accounted for the highest market share in 2022. Asthma holds a prominent position among conditions treated with bronchodilators due to its widespread prevalence and the significant relief bronchodilators provide. Asthma's dominance in bronchodilator usage is driven by its substantial impact on individuals' quality of life. The prevalence of asthma is noteworthy, with a considerable number of people experiencing its symptoms. Bronchodilators quickly alleviate acute symptoms, such as wheezing, shortness of breath, and coughing, and provide swift relief during asthma attacks. This rapid response is a critical factor in establishing bronchodilators as the primary treatment for asthma-related breathing difficulties.

Global Bronchodilators Share, by Region, 2022

The North America bronchodilators market generated the largest revenue in 2022. The prevalence of respiratory conditions like asthma and COPD is notably high in this region, primarily attributed to environmental factors, lifestyle choices, and genetics. Consequently, the demand for effective treatments such as Bronchodilators is substantial. In addition, North America’s advanced healthcare infrastructure and accessibility play a pivotal role. With well-established medical facilities, a network of skilled practitioners, and an informed patient population, the adoption of medical interventions like bronchodilators becomes smoother. Moreover, the region's robust research and development landscape fosters innovation in pharmaceuticals. This leads to the creation of new and improved bronchodilator formulations, boosting their popularity among both medical professionals and patients. Furthermore, public awareness campaigns and health education initiatives enhance understanding of respiratory health and treatment options. Such initiatives encourage individuals to seek timely medical intervention, which frequently involves bronchodilators.

Competitive Scenario in the Global Bronchodilators Market

Investment and agreement are the common strategies followed by the key companies. Some of the leading bronchodilators market players are GSK plc, AstraZeneca, Teva Pharmaceutical Industries Ltd., Cipla Inc., Mylan N.V., Merck & Co., Inc., Novartis AG, Boehringer Ingelheim International GmbH., Sun Pharmaceutical Industries Ltd., and Glenmark Pharmaceuticals Limited.



Historical Market Estimations


Base Year for Market Estimation


Forecast Timeline for Market Projection


Geographical Scope

North America, Europe, Asia-Pacific, and LAMEA

Segmentation by Drug Class

  • Beta-Adrenergic Bronchodilators
  • Xanthine Derivatives
  • Anticholinergic Bronchodilators

Segmentation by Route of Administration

  • Oral
  • Nasal
  • Injectable

Segmentation by Disease

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others

Key Companies Profiled

  • GSK plc.
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Mylan N.V.
  • Merck & Co., Inc.
  • Novartis AG
  • Boehringer Ingelheim International GmbH.
  • Sun Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited


Frequently Asked Questions

A. The size of the global bronchodilators market was over $22.52 billion in 2022 and is projected to reach $31.47 billion by 2032.

A. GSK plc, AstraZeneca, Teva Pharmaceutical Industries Ltd., Cipla Inc., Mylan N.V., and Merck & Co.

A. The North America region possesses great investment opportunities for investors to witness the most promising growth in the future.

A. Agreement and investment are the two key strategies opted by the operating companies in this market.

A. Novartis AG, Boehringer Ingelheim International GmbH., Sun Pharmaceutical Industries Ltd., and Glenmark Pharmaceuticals Limited are investing more on R&D activities.

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed